Sangamo Therapeutics, Inc (SGMOQ) stock
SGMOQOTCBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Số liệu tài chính tới Q1 năm tài chính 2026, quý kết thúc ngày Mar 31, 2026Last filing: 10-Q on May 14, 2026Score 4/30
$0.10−0.01 (-8.17%)
Close on Oct 19, 2026Market cap $39.43MP/E –Yield –
Sangamo Therapeutics r&d expenses
Research and development expenses are spending on new products and technology.
Sangamo Therapeutics's R&D Expenses for the twelve months ending Mar 31, 2026 was $113.23M, up 11.4% year over year. For fiscal 2025 it was $112.67M, up 1.0% from the year before. Over ten years it grew 5.3% a year on average. The highest annual figure on record is $249.90M in fiscal 2022.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $112.67M | +1.0% |
| FY2024 | Dec 31, 2024 | $111.52M | -52.4% |
| FY2023 | Dec 31, 2023 | $234.06M | -6.3% |
| FY2022 | Dec 31, 2022 | $249.90M | +8.3% |
| FY2021 | Dec 31, 2021 | $230.82M | +27.8% |
| FY2020 | Dec 31, 2020 | $180.65M | +23.8% |
| FY2019 | Dec 31, 2019 | $145.92M | +27.0% |
| FY2018 | Dec 31, 2018 | $114.87M | +74.8% |
| FY2017 | Dec 31, 2017 | $65.73M | +0.2% |
| FY2016 | Dec 31, 2016 | $65.62M | -2.4% |
| FY2015 | Dec 31, 2015 | $67.20M | +17.9% |
| FY2014 | Dec 31, 2014 | $56.97M | +53.8% |
| FY2013 | Dec 31, 2013 | $37.04M | +16.8% |
| FY2012 | Dec 31, 2012 | $31.71M | -1.2% |
| FY2011 | Dec 31, 2011 | $32.10M | -3.2% |
| FY2010 | Dec 31, 2010 | $33.15M | +14.4% |
| FY2009 | Dec 31, 2009 | $28.98M | – |
Quarterly r&d expenses
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q1 FY2026 | Mar 31, 2026 | $26.57M | +2.2% |
| Q4 FY2025 | Dec 31, 2025 | $31.44M | +32.8% |
| Q3 FY2025 | Sep 30, 2025 | $28.14M | +1.5% |
| Q2 FY2025 | Jun 30, 2025 | $27.08M | +11.8% |
| Q1 FY2025 | Mar 31, 2025 | $26.01M | -27.5% |
| Q4 FY2024 | Dec 31, 2024 | $23.68M | -53.3% |
| Q3 FY2024 | Sep 30, 2024 | $27.73M | -51.4% |
| Q2 FY2024 | Jun 30, 2024 | $24.22M | -61.6% |
| Q1 FY2024 | Mar 31, 2024 | $35.89M | -43.2% |
| Q4 FY2023 | Dec 31, 2023 | $50.71M | -23.4% |
| Q3 FY2023 | Sep 30, 2023 | $57.09M | -12.3% |
| Q2 FY2023 | Jun 30, 2023 | $63.05M | +5.0% |
| Q1 FY2023 | Mar 31, 2023 | $63.22M | +7.9% |
| Q4 FY2022 | Dec 31, 2022 | $66.18M | +27.8% |
| Q3 FY2022 | Sep 30, 2022 | $65.12M | +4.2% |
| Q2 FY2022 | Jun 30, 2022 | $60.02M | -0.1% |
| Q1 FY2022 | Mar 31, 2022 | $58.58M | +3.8% |
| Q4 FY2021 | Dec 31, 2021 | $51.80M | -1.1% |
| Q3 FY2021 | Sep 30, 2021 | $62.50M | +38.0% |
| Q2 FY2021 | Jun 30, 2021 | $60.09M | +44.7% |
| Q1 FY2021 | Mar 31, 2021 | $56.43M | +36.1% |
| Q4 FY2020 | Dec 31, 2020 | $52.36M | +36.6% |
| Q3 FY2020 | Sep 30, 2020 | $45.29M | +24.8% |
| Q2 FY2020 | Jun 30, 2020 | $41.52M | +13.9% |
| Q1 FY2020 | Mar 31, 2020 | $41.48M | +19.0% |
| Q4 FY2019 | Dec 31, 2019 | $38.33M | +15.3% |
| Q3 FY2019 | Sep 30, 2019 | $36.29M | +26.0% |
| Q2 FY2019 | Jun 30, 2019 | $36.46M | +24.6% |
| Q1 FY2019 | Mar 31, 2019 | $34.85M | +48.0% |
| Q4 FY2018 | Dec 31, 2018 | $33.25M | +71.6% |
| Q3 FY2018 | Sep 30, 2018 | $28.81M | +56.4% |
| Q2 FY2018 | Jun 30, 2018 | $29.26M | +95.2% |
| Q1 FY2018 | Mar 31, 2018 | $23.55M | +81.9% |
| Q4 FY2017 | Dec 31, 2017 | $19.38M | +39.5% |
| Q3 FY2017 | Sep 30, 2017 | $18.43M | +8.3% |
| Q2 FY2017 | Jun 30, 2017 | $14.98M | -23.0% |
| Q1 FY2017 | Mar 31, 2017 | $12.94M | – |
| Q4 FY2016 | Dec 31, 2016 | $13.89M | – |
| Q3 FY2016 | Sep 30, 2016 | $17.01M | – |
| Q2 FY2016 | Jun 30, 2016 | $19.45M | – |
See a number that looks wrong?